BRL-26830A

• Description:

  BRL-26830A is a β-adrenergic receptor agonist. BRL-26830A reduces body weight and increases metabolic rate in obese mouse models. BRL-26830A stimulates insulin release and significantly reduces blood glucose levels in ICR mouse models. BRL-26830A can be used to study endocrine and metabolic diseases such as obesity and diabetes[1][2][2].

• UNSPSC:

  12352100

• Target:

  Adrenergic Receptor

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Smiles:

  O=C(O)/C=C/C(O)=O.O=C(OC)C1=CC=C(C[C@@H](NC[C@@H](O)C2=CC=CC=C2)C)C=C1.[1/2]

• Molecular Formula:

  C19H23NO3.1/2C4H4O4

• Molecular Weight:

  371.45

• References & Citations:

  [1]Connacher AA, et al. Clinical studies with the beta-adrenoceptor agonist BRL 26830A. Am J Clin Nutr. 1992 Jan;55 (1 Suppl) :258S-261S.|[2]Arch JR, et al. Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr. 1983 Oct;38 (4) :549-58. |[3]Yoshida T. The antidiabetic beta 3-adrenoceptor agonist BRL 26830A works by release of endogenous insulin. Am J Clin Nutr. 1992 Jan;55 (1 Suppl) :237S-241S. d

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [87857-42-9]